Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06681233 · ClinicalTrials.gov registry record · NA
Feasibility Study of CBCT for IGRT in Cancer Patients
A NA study of Breast Cancer and Liver Cancer, sponsored by Varian, a Siemens Healthineers Company.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 4
- Study locations
NCT06681233: Recruiting NA study of Breast Cancer and Liver Cancer, sponsored by Varian, a Siemens Healthineers Company.
NCT06681233 is a NA study of Breast Cancer and Liver Cancer that is actively recruiting participants, run by Varian, a Siemens Healthineers Company. The registered enrollment target is 50 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06681233, a NA study of Breast Cancer and Liver Cancer, is actively recruiting participants, sponsored by Varian, a Siemens Healthineers Company.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 4
- Study locations
Study Summary
Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefacts that limit their usability for other tasks in the radiation therapy workflow. Varian Medical Systems, the sponsor of this study, has developed new CBCT imaging technology called HyperSight that so far has demonstrated increased image quality compared with conventional CBCT images. This new HyperSight CBCT imager has previously been built into Varian Halcyon and Ethos treatment machines, where the imager is enclosed in a ring that rotates around the patient. Now, HyperSight has been built into a Varian treatment machine, called TrueBeam, where the imager is mounted on a C-shaped arm that rotates around you to acquire an image. This study is being done to evaluate the image quality of HyperSight CBCT compared to conventional CBCT images, and to determine whether HyperSight CBCT can improve the process of delivering radiation treatments. The goal of this study is to collect images from this new HyperSight-TrueBeam CBCT imager from a variety of patients and locations in the body. The images will be analyzed to determine whether their quality is high enough to use for tasks other than positioning patients for treatment. For example, the study will determine whether the HyperSight images could be used to calculate a radiation plan.
Primary Outcome
The difference in contrast resolution will be evaluated between a standard CBCT image, a CBCT image acquired using HyperSight technology, and a standard fan-beam CT acquired as part of the treatment simulation and planning process
Conditions Studied
Interventions
- DEVICE Comparison of HyperSight CBCT imaging to conventional CBCT imaging.
Study Locations (4)
Ohio
- James Outpatient Center - Columbus
- Ohio State University, Brain and Spine Hospital - Columbus
- The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute - Columbus
- Stefanie Spielman Comprehensive Breast Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-02-19 |
| Est. Completion | 2026-09 |
| Phase | NA |
What NCT06681233 shows while recruiting
NCT06681233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 6 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Comparison of HyperSight CBCT imaging to conventional CBCT imaging. is the first listed.
NCT06681233 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06681233 about?
NCT06681233 is a clinical study titled "Feasibility Study of CBCT for IGRT in Cancer Patients". Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefac...
What is the current status of trial NCT06681233?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-02-19. Estimated completion is 2026-09.
What conditions does trial NCT06681233 study?
This clinical trial studies the following conditions: Breast Cancer, Liver Cancer, Genitourinary Cancer, Head and Neck Cancers, Gastrointestinal Cancers.
What interventions are being tested in trial NCT06681233?
The interventions under investigation include: Comparison of HyperSight CBCT imaging to conventional CBCT imaging. (DEVICE).
Who is sponsoring clinical trial NCT06681233?
This trial is sponsored by Varian, a Siemens Healthineers Company, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06681233 being conducted?
This trial has 4 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06681233's enrollment target sits among peer trials
50 789th of 1224 higher than 410 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI